QT-prolongation in Psychiatric Hospitals
Completed
- Conditions
- QT-prolongation
- Interventions
- Drug: drugs linked with QT-prolongation
- Registration Number
- NCT02043925
- Lead Sponsor
- KU Leuven
- Brief Summary
Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 152
Inclusion Criteria
- inpatient in one of the 6 participating psychiatric hospitals
- QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug
Exclusion Criteria
- age < 18 year
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description psychiatric patients treated with QT-prolonging drugs drugs linked with QT-prolongation -
- Primary Outcome Measures
Name Time Method change in QTc-interval (corrected for heart rate) before and one week after the start of a QT-prolonging drug
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Psychiatrisch Centrum Sint-Jan
🇧🇪Eeklo, Belgium